James Freeman1, Kimberly Wilson2, Ryan Spears3, Victoria Shalhoub4, Paul Sibley5. 1. Siemens Healthcare Diagnostics Inc., 511 Benedict Ave, Tarrytown, NY 10591, USA. Electronic address: james.freeman@siemens.com. 2. Siemens Healthcare Diagnostics Inc., 511 Benedict Ave, Tarrytown, NY 10591, USA. Electronic address: kimberly.s.wilson@siemens.com. 3. Siemens Healthcare Diagnostics Inc., 511 Benedict Ave, Tarrytown, NY 10591, USA. Electronic address: ryan.spears@siemens.com. 4. Siemens Healthcare Diagnostics Inc., 511 Benedict Ave, Tarrytown, NY 10591, USA. Electronic address: victoria.shalhoub@siemens.com. 5. Siemens Healthcare Diagnostics Inc., 511 Benedict Ave, Tarrytown, NY 10591, USA. Electronic address: paul.sibley@siemens.com.
Abstract
OBJECTIVES: The ability of current immunoassays to accurately measure equimolar amounts of 25(OH)D2 and 25(OH)D3 has been recently questioned. This study determined serum 25(OH)D2, 25(OH)D3 and total serum 25(OH)D concentrations in healthy vitamin D2-supplemented subjects by isotope dilution liquid chromatography mass spectrometry (ID-LC-MS/MS); and, evaluated the ability of the Siemens, DiaSorin, Roche, and Abbott Vitamin D Total assays to monitor total serum 25(OH)D concentrations compared to an ID-LC-MS/MS method traceable to the National Institute of Standards and Technology (NIST), and that has achieved certification from the Centers for Disease Control and Prevention (CDC) Vitamin D Standardization Certification Program (VDSCP). DESIGN AND METHODS: Twenty (20) healthy adults, with no history of prior vitamin D supplementation were administered oral vitamin D2 (2400IU/day for 6months). Serum samples (140) from baseline and monthly blood draws were tested. RESULTS: After one month, the mean serum 25(OH)D2 concentrations rose from 0.8 to 43.6nmol/L, whereas 25(OH)D3 concentrations declined from 84.0 to 63.4nmol/L; total serum 25(OH)D concentrations rose from 86.6 to 107.0nmol/L. The overall mean bias to ID-LC-MS/MS was -7.1% for the Siemens ADVIA Centaur assay, -15.3% for the DiaSorin LIAISON assay; -8.4% for the Roche ELECSYS assay and -16.3% for the Abbott ARCHITECT assay. Correlation coefficients (r) were 0.94, 0.79, 0.74, and 0.73; the mean bias for baseline [25(OH) D3-containing] versus six-month [25(OH)D2- and 25(OH)D3-containing] samples was -13.4% and -5.7%; -3.5% and 20.3%, 9.6% and -12.1%, and 0.2% and -17.8%, respectively. CONCLUSIONS: The bias results obtained for the Siemens ADVIA Centaur assay and Roche ELECSYS assay were slightly lower than those for the DiaSorin LIAISON assay and the Abbott ARCHITECT assay, but all 25(OH)D assays demonstrated acceptable performance.
OBJECTIVES: The ability of current immunoassays to accurately measure equimolar amounts of 25(OH)D2 and 25(OH)D3 has been recently questioned. This study determined serum 25(OH)D2, 25(OH)D3 and total serum 25(OH)D concentrations in healthy vitamin D2-supplemented subjects by isotope dilution liquid chromatography mass spectrometry (ID-LC-MS/MS); and, evaluated the ability of the Siemens, DiaSorin, Roche, and Abbott Vitamin D Total assays to monitor total serum 25(OH)D concentrations compared to an ID-LC-MS/MS method traceable to the National Institute of Standards and Technology (NIST), and that has achieved certification from the Centers for Disease Control and Prevention (CDC) Vitamin D Standardization Certification Program (VDSCP). DESIGN AND METHODS: Twenty (20) healthy adults, with no history of prior vitamin D supplementation were administered oral vitamin D2 (2400IU/day for 6months). Serum samples (140) from baseline and monthly blood draws were tested. RESULTS: After one month, the mean serum 25(OH)D2 concentrations rose from 0.8 to 43.6nmol/L, whereas 25(OH)D3 concentrations declined from 84.0 to 63.4nmol/L; total serum 25(OH)D concentrations rose from 86.6 to 107.0nmol/L. The overall mean bias to ID-LC-MS/MS was -7.1% for the Siemens ADVIA Centaur assay, -15.3% for the DiaSorin LIAISON assay; -8.4% for the Roche ELECSYS assay and -16.3% for the Abbott ARCHITECT assay. Correlation coefficients (r) were 0.94, 0.79, 0.74, and 0.73; the mean bias for baseline [25(OH) D3-containing] versus six-month [25(OH)D2- and 25(OH)D3-containing] samples was -13.4% and -5.7%; -3.5% and 20.3%, 9.6% and -12.1%, and 0.2% and -17.8%, respectively. CONCLUSIONS: The bias results obtained for the Siemens ADVIA Centaur assay and Roche ELECSYS assay were slightly lower than those for the DiaSorin LIAISON assay and the Abbott ARCHITECT assay, but all 25(OH)D assays demonstrated acceptable performance.
Authors: Sunni L Mumford; Rebecca A Garbose; Keewan Kim; Kerri Kissell; Daniel L Kuhr; Ukpebo R Omosigho; Neil J Perkins; Noya Galai; Robert M Silver; Lindsey A Sjaarda; Torie C Plowden; Enrique F Schisterman Journal: Lancet Diabetes Endocrinol Date: 2018-05-31 Impact factor: 32.069
Authors: Albert Shieh; Rene F Chun; Christina Ma; Sten Witzel; Briana Meyer; Brandon Rafison; Leon Swinkels; Tonnie Huijs; Sam Pepkowitz; Brett Holmquist; Martin Hewison; John S Adams Journal: J Clin Endocrinol Metab Date: 2016-05-18 Impact factor: 5.958
Authors: Stephen A Wise; Johanna E Camara; Christopher T Sempos; Pierre Lukas; Caroline Le Goff; Stephanie Peeters; Carolyn Q Burdette; Federica Nalin; Grace Hahm; Ramón A Durazo-Arvizu; Adam J Kuszak; Joyce Merkel; Étienne Cavalier Journal: J Steroid Biochem Mol Biol Date: 2021-05-16 Impact factor: 5.011
Authors: Berenice Rivera-Paredez; Nayeli Macías; Mayeli M Martínez-Aguilar; Alberto Hidalgo-Bravo; Mario Flores; Amado D Quezada-Sánchez; Edgar Denova-Gutiérrez; Miguel Cid; Angelica Martínez-Hernández; Lorena Orozco; Manuel Quiterio; Yvonne N Flores; Jorge Salmerón; Rafael Velázquez-Cruz Journal: Nutrients Date: 2018-08-27 Impact factor: 5.717
Authors: Clare F Dix; Judith D Bauer; Ian Martin; Sharon Rochester; Briony Duarte Romero; Johannes B Prins; Olivia R L Wright Journal: Nutrients Date: 2017-10-04 Impact factor: 5.717